Emmaus Life Sciences, Inc. EMMA
Set alert
0.04 USD 0.00 0.00%
At close · Oct 30
0.03 Day range 0.03
0.008 52-week range 0.0879
- YTD
- +170.77%
- 1 year
- +238.14%
- Open
- 0.03
- Prev close
- 0.0352
- Mkt cap
- 2.47M
- Vol
- 25.86K
- Avg vol
- 122.51K
- EPS
- -0.09
- P/E
- 0.00
More statistics
- Low
- 0.03
- High
- 0.03
- Earnings
- Jul 2, 2024
3M chart
Signals (15)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 26, 2026 | 6 days ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bullish | Oct 13, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 2, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 10, 2026 | 1 month ago |
| RSI: Overbought | Sep 1, 2026 | 2 months ago |
| RSI: Overbought | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| SMA: Bearish | Aug 18, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
Next earnings
Jul 2, 2024
Expected Jul 2, 2024. Consensus EPS estimate 0.00.
Financials — quick view
EMMA Revenue — quarterly 10.76M
EMMA Net income — quarterly -1.48M
EMMA EPS — quarterly -0.03
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 19, 2024 | Sep 1, 2024 | 0.00 | -0.01 | — | — |
| Sep 10, 2024 | Mar 1, 2024 | 0.00 | -0.07 | — | — |
| Sep 10, 2024 | Jun 1, 2024 | 0.00 | -0.03 | — | — |
| Jul 2, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -0.01 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -0.03 | — | — |
News
- Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer
- Emmaus Life Sciences Reports Quarterly Financial Results
- Emmaus Life Sciences Reports Quarterly Financial Results
- Emmaus Life Sciences Reports Quarterly Financial Results
- Emmaus Life Sciences Reports Annual Financial Results
- Emmaus Life Sciences Announces Strategic Transaction
- Emmaus Life Sciences Reports Quarterly Financial Results
- Emmaus Life Sciences Reports Quarterly Financial Results
- Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements
- Emmaus Life Sciences Reports Quarterly Financial Results
Your note
Sign in to keep a note on EMMA — it syncs with the Stock Master app.